U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet	1	of	1	

		LIST OF	REFEREN	CES	CITED BY APP	LICANT		
		SERIAL NO.: 10/652,634						
APPLICANT:	:	7-	5		TITLE: CYCLOH	EXYL PR	ROSTAGLAN	JDIN
Old et al		JAN 1 B 201	<b>5</b> 8		ANALOGS AS			·
FILING DAT		2			GROUP:	16-1	4	
28 August 200	3		***		Net assigned	1020	<del>7</del> ·	
Table same	, -	& TRADENS		NT	DOCUMENTS			
*EXAMINER INFTIAL		DOCUMENT NO.	DATE		NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
19	BA	4,060,540	11-29-1977	Fran	ncis et al			
1/3	BB	3,985,798	10-12-1976	Bra	wner et al			
		F	OREIGN PA	TE	NT DOCUMENT	S		
		DOCUMENT NO.	DATE		COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
			<del></del>					(yes/110)
L.,	<del>'</del>	<u> </u>	OTHER	RE	FERENCES	<u> </u>	<u> </u>	L
		(Incl			Date, Pertinent Pages,	etc.)		
しかれ	BC	Brawner et al,	"Prostagland	lins	and congeners. 21	Synthesi	s of some cycl	lohexyl
1/1/		analogs", XP0	02310257, Jo	oum	al of Organic Cher	nistry, 44(	1), 71-5, 1979	•
1 16 1	BD	Lopez-Pelegri	Lopez-Pelegrin et al, "Solution-and soluble-polymer supported asymmetric synthesis of					
1/5		six-membered ring prostanoids", SP002310258, Chemistry-A European Journal, 6(11)						
	1917-1922, 2000					·		
20	BE	Ohuchida et al, "Synthesis of thromboxane A2 analogs-3. (+)-Thiathromboxane A2",						
		XP002310259	, Tetrahedroi	n, 39	9(24), 4269-72, 198	83		ŕ
'R	BF	Crossley et al,	"Cyclohexar	ne ar	nalogs of the prosta	aglandins",	XP00231026	0, Tetrahedron
		Letters, (36), 3	3327 <i>,8</i> 0, 19 <u>7</u> .	1	_ >		057.	
EXAMINER		Will	111	_	DATE CONSID	ERED	106/	OJ
*EXAMINER: I	nitial i	f reference considered wi	nether or not cita	tion	is in conformance with	MPEP 609; D	ray line through	citation if not in
COMMUNICE AND	HOL CC	onsidered. Include copy of	ans town with be	ext co	mmunication to applicar	<b>1</b>	/ /	

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet	_1_	of	1_
-------	-----	----	----

	OF REFERENCES CITED BY APPLICANT
ATTY. DOCKET: 17609(AP)	SERIAL NO.: Not Assigned
APPLICANT: Old et al	TITLE: CYCLOHEXYL PROSTAGLANDIN ANALOGS AS EP,-RECEPTOR AGONISTS
FILING DATE: Submitted herewith	GROUP: 1626

			U.S. PATI	ENT DOCUMENTS	/		
*EXAMINER INIT/A4		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,446,041	8/29/1995	Chan et al			(п аррисавіе)
	AB	4,994,274	2/19/1991	Chan et al			
16	AC	5,028,624	7/2/1991	Chan et al			
	AD	5,034,413	7/23/1991	Chan et al			

F (	UKLIGN PA	TENT DOCUMENT	'S	•	
DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
				_	Q (23 1.0)

OTHER REFERENCES
(Including Author, Title, Date, Pertinent Pages, etc.)

		(Including Author, Title, Date, Pertinent Pages, etc.)
1 //	AE	Bito, L.Z., Biological Protection with Prostaglandins, "Prostaglandins and Related
		Compounds as Potential Ocular Therapeutic Agents", Vol. 1. Chapter 18, 1985, pp.
	<u> </u>	231-252
1	AF	Bito, L.Z., Glaucoma, Applied Pharmacology in the Medical Treatment, "Prostaglandins,
/	1 1	Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents", 1984,
		Chapter 20, pp. 477-505
	AG	Nilsson et al, Invest. Ophthalmol. Vis. Sci. (suppl), 284 (1987), Arvo Abstracts 9-6:00
	AH	Bito, L.Z., Arch. Ophthalmol. "Prostaglandins" "Old Concepts and New Perspectives",
		Vol. 105, pp. 1036-1039 (1987)
	AI	Siebold et al, Prodrug 5 3, "Esterified protaglandin shows 'potent' promise" 1989
	AJ	Lopez-Pelegrin et al, "Solution- and Soluble-Polymer Supported Asymmetric Synthesis
		of Six-Membered Ring Prostanoids", Chem. Eur. J. 2000, 6, 1917-1922
	AK	Hareau et al, "Synthesis of Optically Active 5-(tert-Butyldimethylsiloxy)-2-
<i>Y 1</i>		cyclohexenone and Its 6-Substituted Derivatives as Useful Chiral Building Blocks for
/'/ S		the Synthesis of Cyclohexane Rings. Syntheses of Carvone, Penienone, and
		Penihydrone", J. Am. Chem. Soc. 1999, 121, 3640-3650
0	AL	Casy et al. "METHYL 7-HYDROXYHEPT-5-YNOATE", Organic Synthesis, 415-420
EXAMINE	·	DATE CONSIDERED OF A CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.